
Thijs J Giezen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9788585/publications.pdf Version: 2024-02-01



THUS | CIEZEN

#	Article	IF	CITATIONS
1	Interchangeability of Biosimilars: A European Perspective. BioDrugs, 2017, 31, 83-91.	4.6	153
2	Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review. European Journal of Pharmaceutical Sciences, 2020, 154, 105501.	4.0	11
3	QTc Prolongation in COVID-19 Patients Using Chloroquine. Cardiovascular Toxicology, 2021, 21, 314-321.	2.7	5
4	Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars. Pharmaceuticals, 2021, 14, 189.	3.8	4
5	The effect of medication related clinical decision support at the time of physician order entry. International Journal of Clinical Pharmacy, 2021, 43, 137-143.	2.1	3
6	Switching TNFÎ \pm inhibitors: Patterns and determinants. Pharmacology Research and Perspectives, 2021, 9, e00843.	2.4	3
7	Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review. BioDrugs, 2022, 36, 27-39.	4.6	3
8	Drug-drug interactions with metronidazole and itraconazole in patients using acenocoumarol. European Journal of Clinical Pharmacology, 2020, 76, 1457-1464.	1.9	2
9	Comparison of consistency and complementarity of reporting biosimilar quality attributes between regulatory and scientific communities: An adalimumab case study. Biologicals, 2021, 69, 30-37.	1.4	2
10	Nature and timing of post-approval manufacturing changes of tumour necrosis factor α inhibitor products: A 20-year follow-up study of originators and biosimilars. European Journal of Pharmaceutical Sciences, 2022, 175, 106227.	4.0	1
11	Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept. BioDrugs, 2021, 35, 765-772.	4.6	0